Sermorelin 10mg

Product Specifications

• Compound: Sermorelin (GHRH 1-29)
• Class: Synthetic GHRH analog, 29 amino acids
• Origin: Active N-terminal fragment of human GHRH
• Molecular Weight: ~3358 Da
• Form: Lyophilized powder
• Vial Size: 10mg in 3mL glass vial

Research Background

Sermorelin has been investigated in research literature across several scientific contexts:

• GHRH receptor pharmacology — investigations into receptor binding kinetics, signal transduction, and cellular response mechanisms in pituitary cell models
• GHRH structure-activity relationships — comparative research on the GHRH 1-29 fragment versus full-length GHRH (1-44), examining which structural elements drive receptor binding
• Pituitary cellular biology — studies examining anterior pituitary cell responsiveness to native and synthetic GHRH peptides
• Peptide truncation research — analytical studies on minimal active sequences in GHRH biology
• Comparative GHRH analog research — studies positioning Sermorelin alongside other modified GHRH analogs (such as Tesamorelin) in cellular research contexts

Sermorelin is historically significant in peptide research as one of the earliest characterized GHRH analogs, originally identified through fragment analysis of native human GHRH. Foundational research is available through PubMed (pubmed.ncbi.nlm.nih.gov) and the National Institutes of Health’s PMC database (pmc.ncbi.nlm.nih.gov), where researchers can access peer-reviewed studies on GHRH biology and Sermorelin specifically.